Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

University Hospital Freiburg is a healthcare organization that offers research, education, clinical practice, and treatment programs. Freiburg University Medical Center ensures the possible care for their patients by bundling their knowledge from clinical practice, research, and teaching. Their scientific work aims at the responsible and at the same time rapid introduction of new therapies that save lives and maintain quality of life. Their university clinic offers the medical offspring limitless opportunities to expand their knowledge. It is founded in 1457 in Freiburg, Germany.

Institut Jean Paoli & Irene Calmettes is a non-profit organization engaging in fighting cancer. The company is headquartered in Marseille, France.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

PharmaEssentia Corporation is a biopharmaceutical company that develops treatments for myeloproliferative neoplasms, and hepatitis. They deliver biologics for diseases in the areas of hematology and oncology, with products approved in a diversifying pipeline. Their services include biologics, oncology, rare disease, orphan drugs, orphan disease, drug development, pharmaceuticals, and hematology.

QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France.

The Group's principal activity is to produce pharmaceuticals and chemicals. The operations are carried out through the following divisions: Pharmaceuticals; Bio chemical; Chemicals; Food and Other. Pharmaceuticals include ethical drugs, bulk pharmaceuticals and biological research. Bio chemicals deal with biochemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemicals includes solvents, plasticizes and their raw materials, detergent raw materials and specialty chemicals. Food includes alcoholic beverages, alcohol, seasonings, confectionery, baking ingredients and processed foods. Others include wholesale, commodity distribution and installation of facilities.

GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Zhongke Juyan Stem Cell Co., Ltd., established on 2020-08-10, Business scope includes medical research and experimental development;Biotechnology R&D,technology transfer,technical consulting,Technical Services;Biomaterials R&D;Improvements in bioprocessing technology;commissioned biological cell culture(Except for special approval);umbilical cord,placenta,Umbilical cord blood stem cell technology development and storage services;Cell Product Testing;Cell Drug Development;Cell Therapy Raw Adjuvant Products,Genetic Medicine Technology Development;Research and development of cell beauty products,technical consulting;biological reagent,Research and Development of Biologics,Production,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Toshiba Corporation (株式会社東芝 Kabushiki-gaisha Tōshiba, English: /təˈʃiːbə, tɒ-, toʊ-/) is a Japanese multinational conglomerate headquartered in Tokyo, Japan. Its diversified products and services include information technology and communications equipment and systems, electronic components and materials, power systems, industrial and social infrastructure systems, consumer electronics, home appliances, medical equipment, office equipment, as well as lighting and logistics.

The National Institute of Advanced Industrial Science and Technology (AIST), led by President Chubachi, is a public research institution funded by the Japanese government to a large extent. The present AIST is a rather new research organization established in 2001. However, AIST and its predecessor organizations have been contributing to society through continuous advancement in technologies and support to Japanese industries since 1882. Headquarters of AIST are located in Tsukuba and Tokyo. AIST has over 40 autonomous research units in various innovative research fields, and the units are located at ten research bases and several sites (smaller than research bases) of AIST all over Japan. About 2300 researchers (about 2000 with tenure: about 80 from abroad) and a few thousands of visiting scientists, post-doctoral fellows, and students from home and abroad are working at AIST. About 650 permanent administrative personnel and many temporary staff support research works of AIST.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. These potential therapies could provide novel strategies for the treatment and management of a wide range of tumor types.